What is Humanigen Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Humanigen's cash to debt ratio for the quarter that ended in Mar. 2023 was No Debt (1).
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Humanigen could pay off its debt using the cash in hand for the quarter that ended in Mar. 2023.
(1) Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Humanigen's Cash-to-Debt or its related term are showing as below:
Humanigen Cash-to-Debt Historical Data
The historical data trend for Humanigen's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
Humanigen Cash-to-Debt Chart
|
Humanigen Annual Data
|
|
Trend |
Dec13 |
Dec14 |
Dec15 |
Dec16 |
Dec17 |
Dec18 |
Dec19 |
Dec20 |
Dec21 |
Dec22 |
| Cash-to-Debt |
|
Get a 7-Day Free Trial
|
|
|
0.23 |
0.02 |
No Debt |
2.80 |
No Debt |
|
Humanigen Quarterly Data
|
|
Jun18 |
Sep18 |
Dec18 |
Mar19 |
Jun19 |
Sep19 |
Dec19 |
Mar20 |
Jun20 |
Sep20 |
Dec20 |
Mar21 |
Jun21 |
Sep21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
|
|
|
|
|
|
|
|
2.74 |
1.85 |
No Debt |
No Debt |
No Debt |
Competitive Comparison of Humanigen's Cash-to-Debt
For the Biotechnology subindustry, Humanigen's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Humanigen's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Humanigen's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Humanigen's Cash-to-Debt falls into.
Humanigen Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
Humanigen's Cash to Debt Ratio for the fiscal year that ended in Dec. 2022 is calculated as:
Humanigen had no debt (1).
Humanigen's Cash to Debt Ratio for the quarter that ended in Mar. 2023 is calculated as:
Humanigen had no debt (1).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Humanigen (Humanigen) Business Description
Traded in Other Exchanges
N/A
Address
830 Morris Turnpike, 4th Floor, Short Hills, NJ, USA, 07078
Humanigen Inc is a biopharmaceutical company engaged in the development of proprietary monoclonal antibodies for various oncology indications and to enhance T-cell therapies, making these treatments safer and cost-effective. It focuses on preventing the serious and potentially life-threatening side effects associated with chimeric antigen receptor T-cell (CAR-T) therapy. Its pipeline includes programs such as Lenzilumab, Ifabotuzumab, and HGen005. It has one segment, which is related to the development of pharmaceutical products.
Executives
| Dale Chappell |
10 percent owner |
C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323 |
| Adrian Kilcoyne |
officer: Chief Medical Officer |
533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010 |
| Cameron Durrant |
director |
90, FAIRMOUNT ROAD WEST, CALIFON NJ 07830-3330 |
| Edward P. Jordan |
officer: Chief Commercial Officer |
C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451 |
| John Hohneker |
director |
C/O DIMENSION THERAPEUTICS, INC., 840 MEMORIAL DRIVE 4TH FLOOR, CAMBRIDGE MA 02139 |
| Yili Kevin Xie |
director |
C/O VIEWRAY, INC., 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH 44146 |
| Black Horse Capital Lp |
10 percent owner |
C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323 |
| Black Horse Capital Master Fund Ltd. |
10 percent owner |
C/O OPUS EQUUM, INC., P.O. BOX 788, DOLORES CO 81323 |
| Nomis Bay Ltd. |
10 percent owner |
C/O EOM MANAGEMENT LTD., ANDREW'S PLACE, 51 CHURCH ST., 5TH FLOOR, HAMILTON D0 HM12 |
| Cheryl Buxton |
director |
533 AIRPORT BLVD., SUITE 400, BURLINGAME CA 94010 |
| Cheval Holdings, Ltd. |
10 percent owner |
P.O. BOX 309G, UGLAND HOUSE, GEORGETOWN, GRAND CAYMAN E9 KY1-1104 |
| Black Horse Capital Management Llc |
10 percent owner |
C/O OPUS EQUUM INC., PO BOX 788, DOLORES CO 81323 |
| Robert G. Savage |
director |
C/O EPICEPT CORPORATION, 777 OLD SAW MILL ROAD, TARRYTOWN NY 10591 |
| Rainer J. Boehm |
director |
C/O HUMANIGEN, INC., 1000 MARINA BOULEVARD, SUITE 250, BRISBANE CA 94005-1878 |
| J Gregory Jester |
officer: Chief Financial Officer |
C/O INNOVIVE PHARMACEUTICALS, INC., 555 MADISON AVENUE, 25TH FLOOR, NEW YORK NY 10022 |
Humanigen (Humanigen) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HGENQ has been successfully added to your